157 related articles for article (PubMed ID: 12424535)
1. Chimeric anti-CD20 monoclonal antibody (Mabthera) in remission induction and maintenance treatment of relapsed follicular non-Hodgkin's lymphoma: a phase III randomized clinical trial--Intergroup Collaborative Study.
Van Oers MH; Hagenbeek A; Van Glabbeke M; Teodorovic I
Ann Hematol; 2002 Oct; 81(10):553-7. PubMed ID: 12424535
[No Abstract] [Full Text] [Related]
2. Combined treatment with anti-CD20 (rituximab) and CHOP in relapsed advanced-stage follicular lymphomas.
Domingo-Domènech E; González-Barca E; Estany C; Sureda A; Besalduch J; Fernández de Sevilla A
Haematologica; 2002 Nov; 87(11):1229-30. PubMed ID: 12414357
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
4. Phase I/II study of the rituximab-EPOCT regimen in combination with granulocyte colony-stimulating factor in patients with relapsed or refractory follicular lymphoma including evaluation of its cardiotoxicity using B-type natriuretic peptide and troponin T levels.
Niitsu N; Khori M; Hayama M; Kajiwara K; Higashihara M; Tamaru J
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):697-702. PubMed ID: 15701858
[TBL] [Abstract][Full Text] [Related]
5. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
6. Rituximab plus short-duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the minnie pearl cancer research network.
Hainsworth JD; Litchy S; Morrissey LH; Andrews MB; Grimaldi M; McCarty M; Greco FA
J Clin Oncol; 2005 Mar; 23(7):1500-6. PubMed ID: 15632411
[TBL] [Abstract][Full Text] [Related]
7. [Milestone in healing fatal indolent lymphoma].
Krankenpfl J; 2004; 42(3-4):106-7. PubMed ID: 15311904
[No Abstract] [Full Text] [Related]
8. CHOP chemotherapy followed by Rituximab consolidation as first line treatment in patients with follicular lymphoma. Long-term follow-up of a phase 2 trial.
Jäger G; Quehenberger F; Linkesch W; Neumeister P
Eur J Haematol; 2007 May; 78(5):453-5. PubMed ID: 17419745
[No Abstract] [Full Text] [Related]
9. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up.
Czuczman MS; Weaver R; Alkuzweny B; Berlfein J; Grillo-López AJ
J Clin Oncol; 2004 Dec; 22(23):4711-6. PubMed ID: 15483015
[TBL] [Abstract][Full Text] [Related]
10. Novel treatment strategies in follicular lymphoma.
Buske C; Dreyling H; Unterhalt M; Hiddemann W
Ann Hematol; 2004; 83 Suppl 1():S72. PubMed ID: 15124680
[TBL] [Abstract][Full Text] [Related]
11. Clinical and molecular complete remission of primary duodenal follicular lymphoma following treatment with rituximab and cyclophosphamide, vincristine and prednisone chemotherapy.
Falorio S; Angrilli F; Fioritoni G
Intern Med J; 2009 Oct; 39(10):706-7. PubMed ID: 19849763
[No Abstract] [Full Text] [Related]
12. [Clinical trial of the monoclonal antibody drug mabthera (Rituximab) in the treatment of non-Hodgkin lymphoma].
Korolenko VO; Gershanovich ML; Leenman EE; Tikhonova VV
Vopr Onkol; 2003; 49(4):459-63. PubMed ID: 14569937
[TBL] [Abstract][Full Text] [Related]
13. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
14. Non-Hodgkin's lymphoma (diffuse large B cell lymphoma).
Copson E
Clin Evid; 2005 Jun; (13):1-18. PubMed ID: 16135258
[No Abstract] [Full Text] [Related]
15. Long term remission of Sjögren's syndrome associated aggressive B cell non-Hodgkin's lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone).
Voulgarelis M; Giannouli S; Tzioufas AG; Moutsopoulos HM
Ann Rheum Dis; 2006 Aug; 65(8):1033-7. PubMed ID: 16322082
[TBL] [Abstract][Full Text] [Related]
16. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
Taskinen M; Karjalainen-Lindsberg ML; Nyman H; Eerola LM; Leppä S
Clin Cancer Res; 2007 Oct; 13(19):5784-9. PubMed ID: 17908969
[TBL] [Abstract][Full Text] [Related]
17. [Recent progress in the therapeutic strategy for follicular lymphoma and mantle cell lymphoma].
Ogura M
Rinsho Ketsueki; 2006 Jun; 47(6):495-512. PubMed ID: 16862978
[No Abstract] [Full Text] [Related]
18. A long-lasting third complete remission after second autologous transplant followed by maintenance treatment with rituximab in a patient with diffuse large cell non-Hodgkin's lymphoma.
Ataergin S; Arpaci F; Beyzadeoglu M; Safali M; Ozet A
Am J Hematol; 2006 Dec; 81(12):986-7. PubMed ID: 16886214
[No Abstract] [Full Text] [Related]
19. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
20. High-dose therapy for follicular lymphoma revisited: not if, but when?
Lister TA
J Clin Oncol; 2003 Nov; 21(21):3894-6. PubMed ID: 14517186
[No Abstract] [Full Text] [Related]
[Next] [New Search]
